Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (2391)	7/13/1999 12:53:00 AM
From: Walter Morton	Read Replies (2) \| Respond to of 2742

Today at 11:30 a.m. Be there or be square: IL-1ß As Vaccine Adjuvant; Development and Regulatory Challenges William Lapps, Ph.D., Manager Regulatory Affairs, Pasteur Merieux Connaught IL-1ß is an inflammatory pyrogenic cytokine that has been used in clinical trials to treat cancer. This cytokine has shown to be useful experimentally as an adjuvant for infectious disease antigens. This presentation will discuss past clinical experiences with IL-1 and animal model testing plans to disassociate the adjuvant effect from the inflammatory effect. Assuming completion of proof of concept in the animal models, plans for preclinical safety testing, delivery system strategies and anticipated clinical trial plans will be presented. Who is going to volunteer to buy the paper and post the speach here for all of us to read? Did anybody notice who the first speaker is today: Message 10345549